Prelude Therapeutics

Wilmington, United States

Prelude Therapeutics designs and develops small molecule therapies targeting key drivers of cancer cell growth and resistance.

Apr 2026

Post-IPO Equity

Biopharma Biotechnology Pharmaceutical Therapeutics

Top Investors

RA Capital ManagementOrbiMedFidelitySoleus CapitalIncyte

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Prelude Therapeutics

Who are Prelude Therapeutics's investors?

Prelude Therapeutics's investors include RA Capital Management, OrbiMed, Fidelity, Soleus Capital, Incyte.

Where is Prelude Therapeutics headquartered?

Prelude Therapeutics is headquartered in Wilmington, United States.

What does Prelude Therapeutics do?

Prelude Therapeutics designs and develops small molecule therapies targeting key drivers of cancer cell growth and resistance.

What stage is Prelude Therapeutics at?

Prelude Therapeutics is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated April 21, 2026.

MLA

"Prelude Therapeutics — Funding & Investors." VCBacked, April 21, 2026, https://www.vcbacked.co/company/prelude-therapeutics. Accessed June 4, 2026.

APA

VCBacked. (2026). Prelude Therapeutics — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/prelude-therapeutics

Wikipedia (cite web)

{{cite web |title=Prelude Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/prelude-therapeutics |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated April 21, 2026.

Similar Companies in Biopharma